SCHEMBL17653177

SCHEMBL17653177

CC(C)CCc1nc(Cl)c2cc(Br)ccc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.44
RXFP1 Q9HBX9 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 2/20 0.41
NT5E P21589 1/20 0.39
DPP4 P27487 1/20 0.38
DHODH Q02127 2/20 0.37
PDE4B Q07343 1/20 0.36
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
BCHE P06276 2/20 0.34
ACHE P22303 2/20 0.34
GRIN1 Q05586 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653358 0.86 AAK1 (0.45) AAK1RXFP1CYP1A2CYP2D6CYP2C9
SCHEMBL17653165 0.82 AAK1 (0.43) AAK1RXFP1CYP1A2CYP2D6CYP2C9
SCHEMBL17653336 0.81 AAK1 (0.43) AAK1RXFP1CYP1A2CYP2D6CYP2C9
SCHEMBL17653174 0.81 PDE10A (0.44) AAK1RXFP1CYP1A2CYP2D6CYP2C9
SCHEMBL22101421 0.80 RXFP1 (0.55) RXFP1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL17653194 0.80 DHODH (0.43) AAK1RXFP1HTTDPP4DHODH
SCHEMBL17653322 0.79 AAK1 (0.72) AAK1
SCHEMBL3114949 0.79 HTT (0.47) RXFP1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL17653241 0.78 RXFP1 (0.41) AAK1RXFP1HTTDPP4DHODH
SCHEMBL3871173 0.77 HTT (0.50) RXFP1CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
EP-3200797-A1 QUINAZOLINE-BASED KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-09 EP disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS AAK1, ULK1, NCK1 AAK1 1/4885RXFP1 4427/4885CYP1A2 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.